Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension.
Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension.
复制标题
DOI：
10.1513/pats.200802-020sk
复制
发表时间：
2008-07-15
期刊：
影响因子：
--
通讯作者：
Doyle, Ramona L
中科院分区：
文献类型：
--
作者：
Chen, Hubert;Taichman, Darren B;Doyle, Ramona L
我们对肺动脉高压（PAH）基本病理生理学的理解不断进步，导致治疗选择的数量不断增加。治疗的最终目标是延长生存期，同时改善症状和生活质量。在其他条件下进行的大量研究已将健康相关生活质量（HRQoL）确定为重要的临床终点。然而，直到最近，人们对PAH的HRQoL以及如何最好地测量它知之甚少。在过去的几年里，一些研究开始为这一不断增长的研究领域做出贡献。用于评估HRQoL的工具在研究之间存在差异。这些仪器在PAH中的有效程度取决于其特定的测量特性。在本文中，我们概述了PAH中使用的不同类型的患者报告结局（PRO），特别关注HRQoL的测量。在此过程中，我们回顾了目前的文献中的健康相关生活质量的PAH，总结了现有的数据，从随机对照试验，并讨论了这些结果对未来研究的意义。尽管取得了重大进展，但相对于其他疾病，PAH的HRQoL研究仍然是一个新兴领域。随着PRO使用的持续增加，需要开展额外的工作来开始标准化未来临床试验中此类结局的报告和解释。
Advances in our understanding of the basic pathophysiology of pulmonary arterial hypertension (PAH) has led to an expanding number of therapeutic options. The ultimate goals of therapy are to lengthen survival while improving symptoms and quality of life. A wealth of research in other conditions has established health-related quality of life (HRQoL) to be an important clinical endpoint. Until recently, however, little was known about HRQoL in PAH, and how best to measure it. Over the past few years, several studies have begun contributing to this growing area of research. Instruments used to assess HRQoL have varied between studies. The extent to which these instruments are valid in PAH depend on their specific measurement properties. In this article, we provide an overview of the different types of patient-reported outcomes (PROs) used in PAH, focusing in particular on the measurement of HRQoL. In the process, we review the current literature on HRQoL in PAH, summarize the available data from randomized controlled trials, and discuss the implications of these findings on future research. Despite significant progress, the study of HRQoL in PAH remains a nascent field relative to other conditions. As the use of PROs continues to increase, additional work will be needed to begin standardizing the reporting and interpretation of such outcomes in future clinical trials.